American Society of Hematology
- Health
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces presentation of interim data from its Tenalisib + Romidepsin combination study in patients…
Read More » - World
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
Osaka, Japan & Cambridge, Mass., United States: – Key learnings from real-world data and retrospective studies from nine abstracts are presented…
Read More » - Health
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting
Osaka, Japan & Cambridge, Mass., United States: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored…
Read More »